Welcome to our dedicated page for Sintx Technologies SEC filings (Ticker: SINT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page provides access to SINTX Technologies, Inc. (NASDAQ: SINT) SEC filings, offering detailed insight into the company’s silicon nitride biomaterials business, capital structure, and governance. Filings are sourced in real time from the SEC’s EDGAR system and organized so investors can quickly locate key documents.
Through SINTX’s annual reports on Form 10‑K and quarterly reports on Form 10‑Q, readers can review narrative business descriptions, risk factors, financial statements, and management’s discussion of its advanced ceramics and medical device operations. These reports also describe the company’s focus on infection‑resistant silicon nitride devices, polymer composites, and antipathogenic fabric technologies, as well as its U.S.‑based manufacturing footprint and patent portfolio.
Current reports on Form 8‑K document material events such as FDA 510(k) submissions and clearances, asset purchase agreements, at‑the‑market offering arrangements, warrant inducement transactions, and other financing activities. For example, recent 8‑K filings describe an ATM Offering Agreement with H.C. Wainwright & Co., an inducement agreement related to warrant exercises, and an asset purchase agreement for foot and ankle implant assets.
The DEF 14A proxy statement provides information on board elections, auditor ratification, executive compensation proposals, and equity incentive plans, along with details about the annual meeting of stockholders. Together, these filings help investors understand SINTX’s governance structure and shareholder matters.
Stock Titan’s platform enhances these documents with AI‑powered summaries that highlight important sections, such as business updates, capital‑raising terms, and key risk disclosures, reducing the time needed to interpret lengthy filings. Users can also review Form 4 and related insider transaction filings to see how directors and officers transact in SINTX common stock over time.
By using this page, investors can efficiently navigate SINTX’s 10‑K, 10‑Q, 8‑K, proxy, and insider filings, while AI‑generated insights point to the sections most relevant to the company’s silicon nitride technology platform and financial condition.
Sintx Technologies director Christopher Michael Lyons reported open-market purchases of the company’s common stock. He bought 7,534 shares at $2.90 per share on March 2, 2026 and 758 shares at $2.96 per share on February 25, 2026, bringing his direct holdings to 8,292 shares.
Sintx Technologies, Inc. director Jay M Moyes reported an open-market purchase of 1,000 shares of common stock at $2.91 per share on February 23, 2026. Following this transaction, his directly owned Sintx common stock holdings increased to 4,000 shares.
Sintx Technologies director Mark Lewis Anderson bought additional company stock in the open market. On
SINTX Technologies reported a leadership change and new executive employment terms. Effective March 16, 2026, Eric Olson will stop serving as President but will remain Chairman of the Board and Chief Executive Officer. On the same date, Ryan Elmore will become President and report to the CEO.
Elmore brings over 20 years of leadership experience in medical device and life sciences businesses, including senior commercial and international roles at Invibio, a division of Victrex plc. His executive employment agreement includes a base salary of
Upon starting, he will also receive restricted stock units with a grant date value of
Sintx Technologies, Inc. reported an equity award to its Chief Financial Officer, Kevin Trask. On February 6, 2026, he was granted 60,000 restricted stock units (RSUs) under the company’s 2025 Equity Incentive Plan, at a stated price of $0.00 per unit.
Each RSU represents the right to receive one share of Sintx common stock upon vesting. 20% of the award vested immediately, with the remaining RSUs vesting in additional 20% increments every six months thereafter. Following this grant, Trask directly holds 100,000 derivative securities in the form of RSUs.
Sintx Technologies reported an insider equity award for its Chairman, President and CEO, Eric K. Olson. On February 6, 2026, he was granted 100,000 restricted stock units (RSUs) at a price of $0.00 per unit under the company’s 2025 Equity Incentive Plan.
Each RSU represents the right to receive one share of common stock upon vesting. 20% vested immediately, with the remaining units vesting in 20% increments every six months. Following this grant, Olson directly holds 160,000 derivative securities in the form of RSUs.
Sintx Technologies, Inc. reported that Chief Investment Officer and director Gregg R. Honigblum received an award of 75,000 restricted stock units (RSUs) on February 6, 2026 under the company’s 2025 Equity Incentive Plan.
Each RSU represents the right to receive one share of common stock upon vesting. 20% of the grant vested immediately, with the remaining RSUs vesting in additional 20% installments every six months. Following this award, Honigblum beneficially owned 133,000 derivative securities tied to Sintx common stock in direct ownership.
Sintx Technologies director and Chief Investment Officer Kevin Ontiveros reported significant increases in his ownership of the company’s common stock. On 12/05/2025, he made a series of open-market purchases, each for 5,000 shares of common stock, at prices ranging from $3.77 to $4.07 per share. After these purchases, his directly held stake rose to 139,000 shares.
On the same date, he also received an additional 53,867 common shares at a price of $0.00, described as an issuance incident to the vesting of a Restricted Stock Unit Award. Following this vesting, his directly owned common stock position increased further to 192,867 shares, highlighting both active open-market buying and equity compensation-based ownership growth.
SINTX Technologies furnished an 8-K announcing financial results for the quarter ended September 30, 2025. The results were released via a press release furnished as Exhibit 99.1, which also discusses the company’s use of a non-GAAP financial measure.
The information in Item 2.02 and Exhibit 99.1 is furnished, not filed, and is not incorporated by reference except as expressly stated. The Item 2.02 information is also included under Item 7.01 by reference.
SINTX Technologies filed its Q3 2025 10‑Q, reporting total revenue of $208k (down 74% year over year) and a net loss of $3.539M. Gross profit was $93k, with operating expenses of $3.448M driven by R&D $1.264M and G&A $2.102M. Cash and cash equivalents were $6.250M as of September 30, 2025.
The company continued shifting away from low‑margin OEM work toward proprietary silicon nitride medical devices. It received FDA 510(k) clearance in October 2025 for the SiNAPTIC Foot & Ankle Osteotomy Wedge System, with revenue expected to begin in the first half of 2026. Q3 also included an inducement in which holders exercised warrants for ~$3.8M in gross proceeds, creating a $6.7M deemed dividend.
SINTX strengthened liquidity with a $6.41M at‑the‑market facility established in October 2025 and expects ~$950k savings from subleasing the armor facility. Management states no significant uncertainty regarding its ability to continue as a going concern through at least November 12, 2026. Shares outstanding were 3,851,956 as of November 7, 2025.